Keros Therapeutics, Inc.
KROS
$18.10
$1.277.55%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 3,575.77% | 49,002.70% | 254,413.25% | 2,027.27% | 4,750.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3,575.77% | 49,002.70% | 254,413.25% | 2,027.27% | 4,750.00% |
| Cost of Revenue | -60.35% | 7.38% | 27.32% | 21.71% | 44.19% |
| Gross Profit | 89.24% | 37.41% | 525.77% | -14.03% | -43.08% |
| SG&A Expenses | 3.13% | 45.39% | 1.83% | 17.13% | 7.35% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -49.79% | 14.88% | 21.91% | 20.81% | 36.40% |
| Operating Income | 73.77% | 21.06% | 413.59% | -14.64% | -35.53% |
| Income Before Tax | 83.56% | 27.26% | 467.62% | -13.62% | -34.27% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 86.25% | 32.17% | 444.32% | -14.37% | -34.27% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 86.25% | 32.17% | 444.32% | -14.37% | -34.27% |
| EBIT | 73.77% | 21.06% | 413.59% | -14.64% | -35.53% |
| EBITDA | 74.31% | 21.32% | 416.11% | -14.53% | -35.46% |
| EPS Basic | 87.28% | 39.70% | 402.94% | 14.58% | -5.97% |
| Normalized Basic EPS | 84.79% | 35.34% | 423.44% | 15.14% | -5.97% |
| EPS Diluted | 87.23% | 39.37% | 399.17% | 14.58% | 46.98% |
| Normalized Diluted EPS | 84.79% | 35.34% | 419.80% | 15.14% | -5.97% |
| Average Basic Shares Outstanding | 8.07% | 12.49% | 13.66% | 33.89% | 26.70% |
| Average Diluted Shares Outstanding | 8.07% | 12.49% | 14.95% | 33.89% | 26.70% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |